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View and review
The utility of omega-3 
fatty acids in epilepsy
More than just a farmed tilapia!
Vera C. Terra1, Ricardo M. Arida2, Guilherme M. Rabello3, 
Esper A. Cavalheiro3, Fulvio A. Scorza3
ABSTRACT
The epilepsies are one of the most common serious brain disorders and 20 to 30% of 
people developing epilepsy continue to have seizures and are refractory to treatment 
with the currently available therapies. Approximately one in a 1000 patients with chronic 
epilepsy will die suddenly, unexpectedly, and without explanation, even with post-mortem 
examination and this phenomenon is called sudden unexplained death in epilepsy (SUDEP). 
Understanding the mechanisms underlying SUDEP may lead to the identification of 
previously unrecognized risk factors that are more amenable to correction. We discuss 
here the possible implications of omega-3 fatty acids consumption on SUDEP prevention.
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RESUMO
As epilepsias encontram-se entre as mais sérias doenças neurológicas; 20 a 30% dos 
pacientes com epilepsia continuam apresentando crises e são refratários as terapias 
disponíveis atualmente. Aproximadamente um em cada 1000 pacientes com epilepsia 
crônica irá morrer de forma súbita, não esperada e sem explicação, mesmo com o exame 
pós-morte. Este fenômeno é denominado morte súbita e inesperada em epilepsia 
(SUDEP). Compreender os mecanismos envolvidos nos casos de SUDEP pode levar 
à identificação de fatores ainda não reconhecidos e passíveis de serem corrigidos. 
Discutiremos a seguir as possíveis implicações do consumo do ácido graxo ômega-3 na 
prevenção dos casos de SUDEP.
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The epilepsies are one of the most 
common serious brain disorders and it 
knows no age, racial, social class, geo-
graphic, or national boundaries1. Several 
studies have reported that approximately 
50 million people worldwide have epilep-
sy and that between 70 and 80% of people 
developing epilepsy will go into remission, 
while the remaining patients continue to 
have seizures and are refractory to treat-
ment with the currently available thera-
pies2,3. Furthermore, 80% of the 50 million 
people who have epilepsy live in countries 
with poor resources and this apparent dis-
crepancy between rich and poor countries 
could be due by higher mortality in people 
with epilepsy in the developing world than 
in more affluent countries4,5. In this con-
text, it has been described that each year 
about one in a 1000 patients with chron-
ic epilepsy will die suddenly, unexpectedly, 
and without explanation, even with post-
mortem examination6. In the vernacular 
of the world of epilepsy, this phenomenon 
is called sudden unexplained death in ep-
ilepsy (SUDEP)6. Actually, epilepsy is as-
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sociated with a two- to three-fold increase in mortality 
compared to the general population, and SUDEP is the 
most important direct epilepsy-related cause of death7. 
To date, a number of associated factors for SUDEP have 
been assessed in a number of studies but the results are 
not wholly consistent between them8,9. These include re-
fractoriness of the epilepsy, presence of generalized ton-
ic-clonic seizures, polytherapy with antiepileptic drugs, 
young age, duration of the seizure disorder ranging from 
15 to 20 years, early onset of epilepsy and winter temper-
atures9,10. Additionally, knowledge of risk factors under-
lying SUDEP could guide investigations into its patho-
physiologic mechanisms11. Conversely, understanding the 
mechanisms underlying SUDEP may lead to the identi-
fication of previously unrecognized risk factors that are 
more amenable to correction11. Although different mech-
anisms play a role in different cases, there are indications 
that cardiac arrhythmia during and between seizures play 
a potential pathomechanism for SUDEP9,12. Thus, consid-
ering that efforts to prevent and control seizures should 
be directed towards removing the causes of SUDEP13, 
several experimental and clinical studies have been clear-
ly demonstrated that complementary medical therapies, 
especially omega-3 fatty acids, are often tried by patients 
with epilepsy to control their seizures and hence SUDEP. 
In brief, the first randomized trial of omega-3 supplemen-
tation in patients with chronic epilepsy were encourag-
ing, demonstrating a transient effect on seizure control 
that was not confirmed by other research group, but ad-
ditional trials are required14,15. Although these results did 
not totally confirm that omega-3 fatty acids supplemen-
tation reduce the frequency of epileptic seizures in pa-
tients with refractory epilepsy; they established the safe-
ty of omega-3 supplementation in people with epilepsy15.
Polyunsaturated fatty acids (PUFAs) docosahexaeno-
ic acid (DHA, 22: 6n-3) are major components of mem-
brane phospholipids in brain tissue16. The eicosanoids 
play important roles in neural function including sleep in-
duction, long term potentiation, spatial learning and syn-
aptic plasticity, resolution of inflammation (lipoxins) and 
anti-inflammatory and neuroprotective bioactivity (di-
hydroxy-docosatriene, neuroprotectin D1, formed from 
DHA)17. Diets deficient in omega 3 PUFA lead to reduced 
DHA in the brain and increased turnover of arachidon-
ic acid to eicosanoids, an effect which is overcome by re-
storing the omega 3 PUFA to the diet17.
Studies in mice reported that both omega-3 and ome-
ga-6 fatty acids protect cells from oxidative stress and 
suppress apoptosis and PUFA supplementation may have 
neuroprotective effects18. Also, it has been demonstrat-
ed that n-3 PUFA treatment increased BDNF protein lev-
els in the motor cortex of mice19, enhances hippocampal 
neurogenesis, with an increase in the number of prolifer-
ating neurons and density of dendritic spines of CA1 py-
ramidal neurons in the hippocampus20.
Similarly, studies had demonstrated that DHA re-
duced expressions of tumor necrosis factor-alpha, inter-
leukin-6, nitric oxide synthase, and cyclo-oxygenase-2, in-
duced by interferon-gamma, and induced upregulation of 
heme oxygenase-1 in microglia21.
Using the pilocarpine model of epilepsy, a valuable 
tool to study the pathogenesis of temporal lobe epilepsy 
in human condition, our research group was the first to 
demonstrate that chronic treatment with omega-3 pro-
motes neuroprotection and positive plastic changes in the 
brain of rats with epilepsy22, with a decreased in neuro-
nal death in CA1 and CA3 subfields of the hippocampus. 
This could be attributed to n-3 PUFAs ion channel mod-
ulation23-25, and anti-inflammatory action.
In in vitro studies, DHA has been reported to inhib-
it epileptiform activity and synaptic transmission mainly 
through the frequency-dependent blockade of Na+ chan-
nels in the rat hippocampus23, and to stabilize neuronal 
membrane by suppressing voltage-gated Ca2+ currents26 
and Na+ channels24.
After these research evidences of beneficial effects of 
omega-3 fatty acids in the brain and clinical reports of 
transitory seizure control patients with epilepsy should 
be encourage to eat fish more frequently. The associa-
tion between fish consumption and low rates risk of car-
diovascular disease has been studied nearly four decades 
ago with the consumption of seafood diets by Greenland 
Eskimos, Alaskan Natives and Japanese people residing 
in fishing villages27-30. Recently, several noncardiovascu-
lar actions of fish consumption have also been described, 
suggesting that a regular diet of fish could be of benefit 
in many conditions31, including various central nervous 
system (CNS) diseases32,33. Concerning CNS, we need to 
keep in mind that omega-3 fatty acids (from fatty fish in 
the human diet) also appear effective on the structure, the 
biochemistry, the physiology and thus the function of the 
brain34,35. As we know, the brain is one of the organs with 
the highest level of lipids (fats). Brain lipids, formed of fat-
ty acids, participate in the structure of membranes, for in-
stance 50% fatty acids are polyunsaturated in the gray mat-
ter, 1/3 are of the omega-3 family, and are thus of dietary 
origin36. Thus, seafood (commonly found in fish and fish 
oil) is the only foods that provide large amounts of ome-
ga-331,32,36. Fish can be classified into lean fish that store lip-
id in the liver (eg, cod) or “fatty” (“oily”) fish that store lip-
id in the flesh (eg, salmon, tuna, sardines and herring)31. 
On the other hand, it is very important to emphasise that 
some types of fish may contain high levels of methylmer-
cury, PCBs (polychlorinated biphenyls), dioxins and oth-
er environmental contaminants32,37-39. Levels of these sub-
stances are generally highest in older, larger and predato-
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ry fish32,37-39. So, as the concentration of methylmercury is 
increased in predatory fish, the best seafood choices are 
those with nonpredatory characteristics. Anchovies, At-
lantic herring, salmon, sardines, and trout have low lev-
els of methylmercury, whereas tuna, shark, tilefish, and 
swordfish have high levels of methylmercury32,37-39. A 
study developed by researchers from Wake Forest Uni-
versity School of Medicine characterized the content of 
favorable and unfavorable polyunsaturated fatty acids 
(omega-3 and omega-6) found in commonly eaten fish, 
with closer inspection on the four most commonly con-
sumed farmed fish (salmon, trout, tilapia and catfish)40. Ti-
lapia is now the second (to farmed Atlantic salmon) most 
widely farmed fish in the world40. Based in all these facts, 
what we, as neuroscientists, should be thinking about it? 
Firstly and most important, the health benefits of the 
omega-3 in fish have been well documented40,41. Concern-
ing CNS and associated disorders, the belief that “fish is 
brain food” has been held around the world for well over 
two thousand years33,42,43. Actually, it is clear that fish sup-
plies omega-3 oils, essential for brain and eye tissue de-
velopment in infants; it remains fundamental to those tis-
sues throughout life33,42. Furthermore, the implications of 
omega-3 deficiency on the brain are profound and span 
the entire human life cycle. Beginning in pregnancy, pre-
mature birth and its potential neurologic complications 
may result from omega-3 deficiency33,42. On the other 
hand, one observation deserves explanation here. After 
much discussion, consensus was reached on the impor-
tance around the balance of omega-6 and omega-3 fatty 
acids for homeostasis and normal development44. Thus, 
the ratio of omega-6 to omega-3 is an important determi-
nant of health44. Anthropological evidence suggests that 
human ancestors evolved on a diet in which the ratio of 
omega-6/omega-3 was about 1, whereas in the Western 
diets, the ratio is 15/1 to 17/144. In these lines, it has been 
extensively demonstrated that excessive amounts of ome-
ga-6 and a very high omega-6/omega-3 ratio, as is found 
in today’s Western diets, is associated with serious phys-
iological dysfunctions and contributes to the develop-
ment of several diseases such as heart attacks, throm-
botic stroke, arrhythmia, arthritis, osteoporosis, inflam-
mation, mood disorders, obesity, and cancer44,45. In this 
context, these excessive amounts of omega-6 fatty acids 
upsetting the balance that was characteristic during evo-
lution when our genes were programmed to respond to 
diet and other aspects of the environment44. This consid-
eration was recently demonstrated in an elegant study 
conducted by Weaver and colleagues that developed a di-
etary intervention strategy in which 27 healthy humans 
were fed a controlled diet mimicking the omega-6/ome-
ga-3 ratios of early humans over 5 weeks46. For that, the 
authors then looked at the gene levels of immune sig-
nals and cytokines that impact autoimmunity and aller-
gy in blood cells. Thus, they found that many key signal-
ing genes that promote inflammation were markedly re-
duced compared to a normal diet, including a signaling 
gene for PI3K protein, a critical early step in autoimmune 
and allergic inflammation responses. With these results, 
the authors demonstrated, for the first time in humans, 
that polyunsaturated fatty acids may exert their clinical 
effects via their capacity to regulate the expression of sig-
nal transduction genes and genes for proinflammatory 
cytokines46. In sum, the importance of omega-3 essen-
tial fatty acids in the diet is now evident47. In order to im-
prove the ratio of omega-6/omega-3, it will be necessary 
to decrease the intake of omega-6 fatty acids from vege-
table oils and meat and to increase the intake of omega-3 
fatty acids by increasing the intake of fish to two to three 
times per week47. Finally, the American Heart Associa-
tion released a scientific statement, “Fish Consumption, 
Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Dis-
ease” on the effects of omega-3 fatty acids on heart func-
tion (including antiarrhythmic effects), hemodynamics 
(cardiac mechanics) and arterial endothelial function48. 
On the whole, there are a great number of evidences 
that omega-3 fatty acids are very important for the nor-
mal functioning of the heart and the brain, while PUFA 
themselves are important in membrane structure and 
function17. The inhibitory effect of DHA on nitric oxide 
production and inflammatory process establishment may 
have a main role in omega-3 fatty acids mechanisms of 
action21. Our research group are totally in agreement with 
Professor Russo that concluded in his elegant study that it 
is really necessary to intensify the scientific efforts in or-
der to clarify many controversial aspects of fish consump-
tion in order to make human diet healthier49.
REFERENCES
1. de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. 
Epilepsy Behav 2008;12:540-546.
2. Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003; 
16:165-170.
3. Kwan P, Sander JW. The natural history of epilepsy: an epidemiological view. 
J Neurol Neurosurg Psychiatry 2004;75:1376-1381.
4. Tomson T. Excess mortality in epilepsy in developing countries. Lancet 
Neurol 2006;5:804-805.
5. Scott RA, Lhatoo SD, Sander JW. The treatment of epilepsy in developing 
countries: where do we go from here? Bull World Health Organ 2001;79: 
344-351. 
6. Hirsch LJ, Hauser WA. Can sudden unexplained death in epilepsy be pre-
vented? Lancet 2004;364:2157-2158.
7. Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet 2006; 
367:1087-1100.
8. Surges R, Thijs RD, Tan HL, Sander JW. Medscape. Sudden unexpected 
death in epilepsy: risk factors and potential pathomechanisms. Nat Rev 
Neurol 2009;5:492-504. 
9. Stollberger C, Finsterer J. Cardiorespiratory findings in sudden unexplained/
unexpected death in epilepsy (SUDEP). Epilepsy Res 2004;59:51-60. 
10. Scorza FA, de Albuquerque M, Arida RM, Cavalheiro EA. Sudden unexpect-
ed death in epilepsy: are winter temperatures a new potential risk factor? 
Epilepsy Behav 2007;10:509-510.
Arq Neuropsiquiatr 2011;69(1)
 121
Omega-3: epilepsy
Terra et al.
11. So EL. What is known about the mechanisms underlying SUDEP? Epilepsia 
2008;49:93-98.
12. Scorza FA, Colugnati DB, Pansani AP, Sonoda EY, Arida RM, Cavalheiro 
EA. Preventing tomorrow’s sudden cardiac death in epilepsy today: what 
should physicians know about this? Clinics 2008;63:389-394.
13. Tomson T, Nashef L, Ryvlin P. Sudden unexpected death in epilepsy: cur-
rent knowledge and future directions. Lancet Neurol 2008;7:1021-1031. 
14. Yuen AW, Sander JW, Fluegel D, et al. Omega-3 fatty acid supplementa-
tion in patients with chronic epilepsy: a randomized trial. Epilepsy Behav 
2005;7:253-258.
15. DeGiorgio CM, Miller P. N-3 fatty acids (eicosapentanoic and docosahexa-
noic acids) in epilepsy and for the prevention of sudden unexpected death 
in epilepsy. Epilepsy Behav 2008;13:712-713.
16. Green P, Hermesh H, Monselise A, Marom S, Presburger G, Weizman A. Red 
cell membrane omega-3 fatty acids are decreased in nondepressed patients 
with social anxiety disorder. Eur Neuropsychopharmacol 2006;16:107-113.
17. Tassoni D, Kaur G, Weisinger RS, Sinclair AJ. The role of eicosanoids in the 
brain. Asia Pac J Clin Nutr. 2008;17(Suppl 1):S220-S228.
18. Kim SJ, Zhang Z, Saha A, Sarkar C, Zhao Z, Xu Y, Mukherjee AB. Omega-3 
and omega-6 fatty acids suppress ER- and oxidative stress in cultured neu-
rons and neuronal progenitor cells from mice lacking PPT1. Neurosci Lett 
2010;2:292-296.
19. Bousquet M, Gibrat C, Saint-Pierre M, Julien C, Calon F, Cicchetti F. Mod-
ulation of brain-derived neurotrophic factor as a potential neuroprotec-
tive mechanism of action of omega-3 fatty acids in a parkinsonian animal 
model. Prog Neuropsychopharmacol Biol Psychiatry 2009;13:1401-1408.
20. He C, Qu X, Cui L, Wang J, Kang JX. Improved spatial learning performance 
of fat-1 mice is associated with enhanced neurogenesis and neuritogene-
sis by docosahexaenoic acid. Proc Natl Acad Sci U S A. 2009;7:11370-11375.
21. Lu DY, Tsao YY, Leung YM, Su KP. Docosahexaenoic acid suppresses neu-
roinflammatory responses and induces heme oxygenase-1 expression in 
BV-2 microglia: implications of antidepressant effects for omega-3 fatty ac-
ids. Neuropsychopharmacology 2010, in press.
22. Ferrari D, Cysneiros RM, Scorza CA, et al. Neuroprotective activity of ome-
ga-3 fatty acids against epilepsy-induced hippocampal damage: quantifi-
cation with immunohistochemical for calcium-binding proteins. Epilepsy 
Behav 2008;13:36-42.
23. Young C, Gean P, Chiou LC, Shen Y. Docosahexaenoic acid inhibits 
synaptic transmission and epileptiform activity in the rat hippocampus. 
Synapse 2000;37:90-94.
24. Xiao YF, Kang JX, Morgan JP, Leaf A. Blocking effects of polyunsaturated fat-
ty acids on Na+ channels of neonatal rat ventricular myocytes. Proc Natl 
Acad Sci USA 1995;92:11000-11004.
25. Xiao Y, Li X. Polyunsatured fatty acids modify mouse hippocampal neu-
ronal excitability during excitotoxic or convulsant stimulation. Brain Res 
1999;846:112-121.
26. Xiao YF, Gomez AM, Morgan JP, Lederer WJ, Leaf A. Suppression of 
voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult 
and neonatal rat ventricular myocytes. Proc Natl Acad Sci USA 1997;94: 
4182-4187.
27. He K. Fish, long-chain omega-3 polyunsaturated fatty acids and preven-
tion of cardiovascular disease: eat fish or take fish oil supplement? Prog 
Cardiovasc Dis 2009;52:95-114.
28. Middaugh JP. Cardiovascular deaths among Alaskan Natives,1980-86. Am 
J Public Health 1990;80:282-285.
29. Kagawa Y, Nishizawa M, Suzuki M, et al. Eicosapolyenoic acids of serum 
lipids of Japanese islanders with low incidence of cardiovascular diseases. 
J Nutr Sci Vitaminol 1982;28:441-453.
30. Bang HO, Dyerberg J, Hjøorne N. The composition of food consumed by 
Greenland Eskimos. Acta Med Scand 1976;200:69-73.
31. Calder PC, Yaqoob P. Understanding omega-3 polyunsaturated fatty acids. 
Postgrad Med 2009;121:148-157.
32. Scorza FA, Cysneiros RM, Terra VC, et al. Omega-3 consumption and 
sudden cardiac death in schizophrenia. Prostaglandins Leukot Essent Fatty 
Acids 2009;81:241-245.
33. Mazza M, Pomponi M, Janiri L, Bria P, Mazza S. Omega-3 fatty acids and 
antioxidants in neurological and psychiatric diseases: an overview. Prog 
Neuropsychopharmacol Biol Psychiatry 2007;31:12-26.
34. Bourre JM. Dietary omega-3 fatty acids and psychiatry: mood, behaviour, 
stress, depression, dementia and aging. J Nutr Health Aging 2005;9:31-38.
35. Bourre JM. Effects of nutrients (in food) on the structure and function of 
the nervous system: update on dietary requirements for brain. Part 2: mac-
ronutrients. J Nutr Health Aging 2006;10:386-399.
36. Bourre JM. Omega-3 fatty acids in psychiatry. Med Sci 2005;21:216-221.
37. Smith KM, Sahyoun NR. Fish consumption: recommendations versus advi-
sories, can they be reconciled? Nutr Rev 2005;63:39-46.
38. Jeejeebhoy KN. Benefits and risks of a fish diet: should we be eating more 
or less? Nat Clin Pract Gastroenterol Hepatol 2008;5:178-179.
39. Fish: friend or foe? In addition to heart-healthy omega-3 fats, seafood can 
carry mercury and other toxins. For most people, the benefits of eating fish 
far outweigh the risks. Harv Heart Lett 2007;17:4-6.
40. Weaver KL, Ivester P, Chilton JA, Wilson MD, Pandey P, Chilton FH. The 
content of favorable and unfavorable polyunsaturated fatty acids found in 
commonly eaten fish. J Am Diet Assoc 2008;108:1178-1185.
41. Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident 
atrial fibrillation. Circulation 2004;110:368-373.
42. Innis SM. Omega-3 Fatty acids and neural development to 2 years of age: 
do we know enough for dietary recommendations? J Pediatr Gastroenterol 
Nutr 2009;48 (Suppl):S16-S24.
43. Scorza FA, Cysneiros RM, Terra VC, Arida RM, Scorza CA, Cavalheiro EA. From 
Galapagos to the labs: Darwinian medicine and epilepsy today. Epilepsy 
Behav 2009;16:388-390.
44. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essen-
tial fatty acids. Biomed Pharmacother 2002;56:365-379.
45. Calder PC. N-3 polyunsaturated fatty acids, inflammation, and inflammato-
ry diseases. Am J Clin Nutr 2006;83:1505-1519.
46. Weaver KL, Ivester P, Seeds M, Case LD, Arm JP, Chilton FH. Effect of di-
etary fatty acids on inflammatory gene expression in healthy humans. J 
Biol Chem 2009;284:15400-15407. 
47. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune 
diseases. J Am Coll Nutr 2002;21:495-505.
48. Kris-Etherton PM, Harris WS, Appel LJ. American Heart Association. Nu-
trition Committee. Fish consumption, fish oil, omega-3 fatty acids, and 
cardiovascular disease. Circulation 2002;106:2747-2757.
49. Russo GL. Dietary n-6 and n-3 polyunsaturated fatty acids: from biochem-
istry to clinical implications in cardiovascular prevention. Biochem Phar-
macol 2009;77:937-946. 
